Paysign, Inc.

Paysign is a small-cap prepaid-debit-card and payment-solutions provider — specifically serving plasma-donation and pharma-copay-assistance verticals. The 2026 story is about whether the plasma-vertical recovery plus continued pharma-copay-scale supports continued upward re-rating.

• The Q2 mechanics were extraordinary: revenue of $28.3M grew ~48% YoY at a 63% gross margin and 25% operating margin, EPS of $0.12 beat consensus of $0.06 by 83% — for a business at 44x TTM PE with a 9.7% FCF yield and consensus FY26 EPS of $0.24 putting the forward at ~54x, expensive in absolute terms but reasonable versus the growth trajectory if the beat cadence continues.
• The verticals-recovery commentary is the specific structural anchor: plasma called out of its industry funk plus pharma described as booming — that's the specific vertical-market commentary that supports continued upward guide-raise cycles, and the 25% incremental-margin expansion validates the operating leverage from vertical concentration.
• The tape confirms accelerating: shares sit at the 99th percentile of the 52-week range, +50% vs the 50-day and +118% vs the 200-day — that's the specific breakout-pattern of a name where the operational execution plus vertical-recovery narrative has re-rated the entire multiple structure. Multiple insider M-Exempts on Aug 4 (Triplett, Mina, Henry, all directors) and a $1.78M CEO sale on Aug 6 are option-linked, though the size is meaningful.

What extends the accelerating trajectory is the Nov 11 print confirming Q2's vertical-recovery cadence continues plus specific commentary on new-vertical-expansion; what interrupts it is a specific plasma-vertical demand slowdown or additional insider distribution beyond option-linked activity.